Likewise, allo-HSCT after CD19-targeted CAR-T-cell therapy was found to be safe and effective at treating B-cell chronic lymphocytic leukemia (B-CLL) and non-Hodgkin lymphoma (NHL) [199]. This evidence concerns the gene CD19 and non-Hodgkin lymphoma.